Top 50 High-Value Medical Consumables Sales Released: Leading Players Include Lepu, MicroPort, and Johnson & Johnson

Medicine Network, August 5 – On August 1, the Kunming Municipal Health Commission released data on the procurement of pharmaceuticals and high-value medical consumables by municipal-level public hospitals in Kunming from January to June 2019.

 

According to statistics, in the first half of the year, Kunming municipal-level publicHospitalTotalProcurementPharmaceuticalsRMB 899 million, with RMB 211 million spent on the procurement of high-value medical consumables.

 

 

Meanwhile, the official website disclosed information regarding the procurement timelines, unit prices, quantities, and manufacturers of pharmaceuticals and high-value medical consumables for each hospital.

 

This can be seen from the procurement volume of high-value consumables.

 

The top-ranked procurement by amount was the cobalt-based alloy sirolimus-eluting stent system produced by Lepu Medical, with a total value of approximately RMB 1.236 million.

 

Second is Shanghai MicroPortMedical DevicesThe Company's coronary sirolimus-eluting cobalt-based alloy stent system, with a total amount of RMB 1.045 million.

 

Third is the drug-eluting stent system (sirolimus) produced by Shandong Jiwei Medical, with a total amount of 1.032 million yuan.

 

In terms of total amount, Lepu Medical Technology (Beijing) Co., Ltd. ranked first with a procurement value of RMB 8.017 million for six products: drug-eluting stent system (sirolimus), biodegradable drug-eluting coronary stent system, branched aortic stent graft and delivery system, single-use myocardial protective solution perfusion device, coronary sirolimus-eluting cobalt-based alloy stent system, and cobalt-based alloy sirolimus-eluting stent system.

 

Chaori Yingda Science and Trade (Beijing) Co., Ltd. and Sino Medical Sciences Technology Inc. ranked second and third, with RMB 5.785 million and RMB 3.823 million, respectively. Details are shown in the table below:

 

 

Regarding the progress of procurement, the Yunnan Provincial Medical Products Administration pointed out that medical institutions and drug manufacturers and distributorsEnterpriseDuring transactions, transaction information—including price, quantity, manufacturer, and batch number—must be carefully verified to ensure that online transaction data aligns with actual conditions, thereby minimizing the frequent occurrence of pharmaceutical product returns. Pharmaceutical manufacturers and distributors shall regularly conduct inventory checks, respond promptly to online orders, and ensure adequate supply.